| Bioactivity | JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagonist with good pharmacokinetic properties, with pKis of 8.49, 7.99, and 7.70 for human, rat, and dog CCK2 receptors, respectively. The dual function of CCK2 receptors in regulating gastric acid secretion and growth of the gastrointestinal mucosa make this an attractive and novel target for the treatment of gastroesophageal reflux disease[1]. |
| Target | pKi: 8.49 (human CCK2), 7.99 (rat CCK2), 7.70 (dog CCK2) |
| Name | JNJ-26070109 |
| CAS | 844645-08-5 |
| Formula | C23H17BrF2N4O3S |
| Molar Mass | 547.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Magda F Morton, et al. JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability. J Pharmacol Exp Ther. 2011 J |
JNJ-26070109
CAS: 844645-08-5 F: C23H17BrF2N4O3S W: 547.37
JNJ-26070109 is a high-affinity, competitive, orally bioactive, and selective cholecystokinin 2 (CCK2) receptor antagoni
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.